SCHEMBL1855994

SCHEMBL1855994

Clc1ccc2c(c1)Nc1ccc(Cl)cc1S2.O=C(Cl)Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 8/20 0.65
BCHE P06276 1/20 0.65
ACHE P22303 1/20 0.65
GAA P10253 4/20 0.46
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPK13 O15264 1/20 0.46
DAPK3 O43293 1/20 0.46
ROCK2 O75116 1/20 0.46
CHEK2 O96017 1/20 0.46
PIM1 P11309 1/20 0.46
CDK2 P24941 1/20 0.46
RECQL P46063 1/20 0.46
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
CSNK2A1 P68400 1/20 0.46
PRKCZ Q05513 1/20 0.46
PRKAA1 Q13131 1/20 0.46
ROCK1 Q13464 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28117917 0.91 NOX1 (0.76) NOX1BCHEACHEGAAMAPT
SCHEMBL1509784 0.89 NOX1 (0.68) NOX1BCHEACHEGAAMAPT
SCHEMBL1509893 0.89 NOX1 (0.84) NOX1BCHEACHEGAAMAPT
SCHEMBL28117966 0.84 NOX1 (0.81) NOX1BCHEACHEGAAMAPT
SCHEMBL7673182 0.84 NOX1 (0.62) NOX1BCHEACHEGAAMAPT
SCHEMBL30697368 0.84 NOX1 (0.62) NOX1BCHEACHEGAAMAPT
SCHEMBL29276729 0.83 NOX1 (0.65) NOX1BCHEACHEGAAMAPT
SCHEMBL4670416 0.83 NOX1 (0.79) NOX1BCHEACHEGAAMAPT
Hydrochloric Acid SCHEMBL30448208 0.82 NOX1 (0.60) NOX1BCHEACHEGAAMAPT
Hydrochloric Acid SCHEMBL20495637 0.82 NOX1 (0.60) NOX1BCHEACHEGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317454-B1 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMA (US) 2011-05-25 EP disclosed
US-6800619-B2 UREA HETEROCYCLICCARBONYL-SUBSTITUTED ASPARTIC OR GLUTAMIC ACID DERIVATIVES VERTEX PHARMACEUTICALS INCORPORATED 2004-10-05 US disclosed
EP-1317454-A2 CASPASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2003-06-11 EP disclosed
US-20020058630-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2002-05-16 US disclosed
WO-2002022611-A2 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058630-A1 Caspase inhibitors and uses thereof CASP2, CASP3, CASP7 NOX1 2272/4885BCHE 470/4885ACHE 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.